References

How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 136 CE courses, most popular
$95Add to cart
Pick Your Courses
Up to 8 CE hours
$50Add to cart
Individual course$20Add to cart
The page below is a sample from the LabCE course Alzheimer's Biomarkers: Overview of existing and future biomarkers. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Alzheimer's Biomarkers: Overview of existing and future biomarkers (online CE course)
References

ADmark Phophso-Tau/Total Tau/A Beta42 Analysis and Interpretation, CSF, Athena Diaagnostics, Available at https://www.athenadiagnostics.com/view-full-catalog/a/admark-reg;-phospho-tau-total-tau-ab42-csf-analysi. Accessed 1/31/2020.
ADmark APOE Genotype Analysis and Interpretation, Athena Diagnostics, available at https://www.athenadiagnostics.com/view-full-catalog/a/admark-reg;-apoe-genotype-analysis-interpretation. Accessed 1/31/2020.
Alzheimer’s Association Recommendations on Biomarkers, Diagnostic Criteria Guidelines, available at https://www.alz.org/research/for_researchers/diagnostic-criteria-guidelines. Accessed 1/31/2020.
Alzheimer’s Disease: Overview and Testing Services: Quest Diagnostics, available at https://www.questdiagnostics.com/home/physicians/testing-services/condition/neurology/Alzheimers-disease.html. Accessed 1/31/2020.
Alzheimer’s Disease: Overview. U S National Library of Medicine, available at https://medlineplus.gov/alzheimersdisease.html. Accessed 1/31/2020.
Alzheimer’s Disease Diagnosis: National Institute on Aging, NIH, available at https://www.nia.nih.gov/health/how-alzheimers-disease-diagnosed. Accessed 1/31/2020.
APOE Genotyping: Alzheimer’s Disease. AACC Lab tests online, available at https://labtestsonline.org/tests/apoe-genotyping-alzheimer-disease. Accessed 1/31/2020.
Amyloid-beta precursor Protein (APP), available at https://pdb101.rcsb.org/motm/79. Accessed 1/31/2020.
BCBSTN Policy: Biochemical Markers for Alzheimer’s Disease, reviewed 7/11/19, available at https://www.bcbst.com/mpmanual/Biochemical_Markers_for_Alzheimers_Disease.htm. Accessed 1/31/2020.
Beta-Amyloid 42/40 Ratio and Apolipoprotein E (APOE) Isoform Panel, CSF: Quest Diagnostics, available at https://testdirectory.questdiagnostics.com/test/test-detail/94628/?cc=MASTER (accessed 1/31/2020) and https://testdirectory.questdiagnostics.com/test/test-guides/TS_AbetaApoE/beta-amyloid-4240-ratio-and-apolipoprotein-e-apoe-isoform-panel-csf?p=td. Accessed 1/31/2020.
Biomarkers for Alzheimer's disease: current status and prospects for the future. Blennow K, and Zetterberg H, J Intern Med. 2018 Dec;284(6):643-663. doi: 10.1111/joim.12816. Epub 2018 available at https://www.ncbi.nlm.nih.gov/pubmed/30051512. Accessed 1/31/2020.
Biomarkers for Alzheimer’s Disease in Saliva: A Systematic Review. H Gleerup et al, Disease Markers, Vol 2019, Article 4761054. Available at : https://www.hindawi.com/journals/dm/2019/4761054/. Accessed 1/31/2020.
Biomarkers for Dementia Detection and Research, NIH, National Institute on Aging, April 2018, Available at https://www.nia.nih.gov/health/biomarkers-dementia-detection-and-research. Accessed 1/31/2020.
Blood-based Biomarkers: Alzheimer's disease and blood-based biomarkers – potential contexts of use, M Zverova, April 2018, Available at Neuropsychiatric Disease and Treatment » Volume 14 available at https://www.dovepress.com/alzheimers-disease-and-blood-based-biomarkers-potential-contexts-of-us-peer-reviewed-fulltext-article-NDT (accessed 1/31/2020) and https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055879/. Accessed 1/31/2020.
Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic: H Hampel et al, Neurology, Vol 14, Pgs 639-652, 2018, Available at: https://www.nature.com/articles/s41582-018-0079-7. Accessed 1/31/2020.
Blood-based molecular biomarkers for Alzheimer’s disease, H. Zetterberg and S Burnham, Molecular Brain volume 12, Article number: 26 (2019), available at https://molecularbrain.biomedcentral.com/articles/10.1186/s13041-019-0448-1. Accessed 1/31/2020.
Blood Test Detects Onset of Alzheimer’s a Decade Early, News Release, April 8, 2019, Alzheimer’s Association, available at https://www.alzheimers.net/12-3-14-blood-test-detects-alzheimers-early/, Accessed 1/31/2020.
Blood Test for Alzheimer’s: Scientist close in on Blood Test: July 15, 2019, Press Release, available at https://www.statnews.com/2019/07/15/scientists-close-in-on-blood-test-alzheimers/. Accessed 1/31/2020.
Current State of Alzheimer’s Fluid Biomarkers, J Molinuevo et al, Acta Neuropathologica, Vol 136, Issue 6, pp 821-853, December 2018. Available at https://link.springer.com/article/10.1007/s00401-018-1932-x. Accessed 1/31/2020.
CSF AND BLOOD BIOMARKERS OF EARLY-ONSET ALZHEIMER’S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS. G Virk et al, Alzheimer’s & Dementia, Alzheimer’s Association, July 2018, Vol 14, Issue 7, Sup page P1158. available at : https://www.alzheimersanddementia.com/article/S1552-5260(18)31757-6/abstract. Accessed 1/31/2020.
Diagnosis and Treatment: Alzheimer’s disease: Mayo Clinic, available at https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/diagnosis-treatment/drc-20350453. Accessed 1/31/2020.
Facts and Figures: Alzheimer’s Disease, Alzheimer’s Association, available at https://www.alz.org/alzheimers-dementia/facts-figures. Accessed 1/31/2020.
Fact Sheet on Alzheimer’s Disease, National Institute on Aging, NIH, available at https://www.nia.nih.gov/health/alzheimers-disease-fact-sheet. Accessed 1/31/2020.
Genetic Testing Fact Sheet: Alzheimer’s Dementia, Diagnosis, Alzheimer’s Association, available at https://www.alz.org/alzheimers-dementia/diagnosis/medical_tests (accessed 1/31/2020) and Genetic Testing Fact Sheet. Accessed 1/31/2020.
Genetics and Alzheimers, Alzheimers Association, available at https://www.alz.org/alzheimers-dementia/what-is-alzheimers/causes-and-risk-factors/genetics. Accessed 1/31/2020.
Genetics and Genetic Testing: Alzheimer’s Disease. National Institute on Aging, NIH, available at: https://www.nia.nih.gov/health/alzheimers-disease-genetics-fact-sheet. Accessed 1/31/2020.
Global Biomarker Standardization Consortium (GBSC), Alzheimer’s Association, available at https://www.alz.org/research/for_researchers/partnerships/biomarker_consortium. Accessed 1/31/2020.
High performance plasma amyloid-β biomarkers for Alzheimer's disease. A Nakamura et al, Nature, Feb 8 2018, 554 (7691), 249-254, available at https://www.ncbi.nlm.nih.gov/pubmed/29420472. Accessed 1/31/2020.
Labcorp Tau protein and Beta-amyloid test, Labcorp Inc, available at https://www.labcorp.com/help/patient-test-info/tau-protein-and-beta-amyloid. Accessed 1/31/2020.
Labcorp APOE Alzheimer’s Risk Test, Labcorp Inc, available at https://www.labcorp.com/test-menu/20331/iapoe-i-alzheimers-risk. Accessed 1/31/2020.
Stages of Alzheimer’s Disease: Alzheimer’s Association, Available at: https://www.alz.org/alzheimers-dementia/stages. Accessed 1/31/2020.
Symptoms and Causes: Alzheimer’s Disease, Mayo Clinic, available at https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/symptoms-causes/syc-20350447. Accessed 1/31/2020.
Tau Protein and Phospho-Tau Protein: ADMark Test, Athena Diagnostics, available at https://www.athenadiagnostics.com/view-full-catalog/a/admark-reg;-phospho-tau-total-tau-ab42-csf-analysi#section2. Accessed 1/31/2020.
Tau Protein and Alzheimer’s Disease: What’s the Connection? J Ellison MD, Swank Memory Care Center, Christiana Care Health System, available at https://www.brightfocus.org/alzheimers-disease/article/tau-protein-and-alzheimers-disease-whats-connection. Accessed 1/31/2020.
Tau Protein and Beta Amyloid, AACC Lab tests online, Available at https://labtestsonline.org/tests/tau-protein-and-beta-amyloid. Accessed 1/31/2020.
Tau Protein and Phospho-Tau Protein: overview, Athena Diagnostics, available at https://www.athenadiagnostics.com/view-full-catalog/a/admark-reg;-phospho-tau-total-tau-ab42-csf-analysi. Accessed 1/31/2020.
The Physiological Roles of Amyloid-β Peptide Hint at New Ways to Treat Alzheimer's Disease, H Brothers et al, April 25, 2018, Aging Neurosci. available https://www.frontiersin.org/articles/10.3389/fnagi.2018.00118/full. Accessed 1/31/2020.
Treatment and Diagnosis: Alzheimer’s Disease, Mayo Clinic, available at https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/diagnosis-treatment/drc-20350453. Accessed 1/31/2020.
Treatment of Alzheimer’s Disease, National Institute on Aging, NIH, available at https://www.nia.nih.gov/health/alzheimers/treatment. Accessed 1/31/2020.
Treatment of Alzheimer’s Disease: How is Alzheimer’s Disease Treated? National Institute on Aging, NIH, available at https://www.nia.nih.gov/health/how-alzheimers-disease-treated. Accessed 1/31/2020.
Additional References:
Alzheimer's Association. 2017 Alzheimer's disease facts and figures. Alzheimer's & Dementia. 2017;13:325-373.
Bird TD. Alzheimer disease overview. In: Pagon RA, Adam MP, Ardinger HH, et al, eds. GeneReviews. Seattle, Wash: University of Washington; 2014. PubMed 20301340 Accessed 1/31/2020.
Du, Y; Dodel, R; Hampel, H; Buerger, K; Lin, S; Eastwood, B; Bales, K; Gao, F; et al. (2001). "Reduced levels of amyloid beta-peptide antibody in Alzheimer disease". Neurology. 57 (5): 801–5. doi:10.1212/wnl.57.5.801. PMID11552007. Accessed 1/31/2020
Gustaw, KA; Garrett, MR; Lee, HG; Castellani, RJ; Zagorski, MG; Prakasam, A; Siedlak, SL; Zhu, X; et al. (2008). "Antigen-antibody dissociation in Alzheimer disease: A novel approach to diagnosis". Journal of Neurochemistry. 106 (3): 1350–6. doi:10.1111/j.1471-4159.2008.05477.x. PMC2575068. PMID18485104. Accessed 1/31/2020.
Herukka SK, Simonsen AH, Andreasen N, et al. Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimers Dement. 2017;13:285-295.
Hampel, Harald; Shen, Yong; Walsh, Dominic M.; Aisen, Paul; Shaw, Les M.; Zetterberg, Henrik; Trojanowski, John Q.; Blennow, Kaj (2010). "Biological markers of amyloid β-related mechanisms in Alzheimer's disease". Experimental Neurology. 223 (2): 334–46. doi:10.1016/j.expneurol.2009.09.024. PMC2896007. PMID19815015. Accessed 1/31/2020.
Hansson, O; Zetterberg, H; Vanmechelen, E; Vanderstichele, H; Andreasson, U; Londos, E; Wallin, A; Minthon, L; Blennow, K (2010). "Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment". Neurobiology of Aging. 31 (3): 357–67. doi:10.1016/j.neurobiolaging.2008.03.027. PMID18486992. Accessed 1/31/2020.
Janelidze S, Zetterberg H, Mattsson N, et al. CSF Abeta42/Abeta40 and Abeta42/Abeta38 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol. 2016;3:154-165.
Lewczuk P, Matzen A, Blennow K, et al. Cerebrospinal fluid Abeta42/40 corresponds better than Abeta42 to amyloid PET in Alzheimer's disease. J Alzheimers Dis. 2017;55:813-822.
Maiti TK, Konar S, Bir S, et al. Role of apolipoprotein E polymorphism as a prognostic marker in traumatic brain injury and neurodegenerative disease: a critical review. Neurosurg Focus. 2015;39:E3. doi:10.3171/2015.8.FOCUS15329
Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia—meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand. 2009;119:252-265.
Simonsen AH, Herukka SK, Andreasen N, et al. Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimers Dement. 2017;13:274-284